Verve Therapeutics, Inc.

Industry

  • Biotechnology
    • Nanotechnology, Chips, etc.
    • Drug Discovery Technologies
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
See more in Biomedtracker

Latest on Verve Therapeutics, Inc.

Scrip

Lilly Licenses Sangamo’s Capsid Technology For CNS Gene Therapy

 
• By Alaric DeArment

Who: Sangamo Therapeutics/Eli Lilly What: Lilly signed a deal with Sangamo to license the gene therapy company’s STAC-BBB adeno-associated viral vector capsid for up to five potential neurological

Scrip

Peter Marks’ Departure From FDA Rattles Biopharma Industry

 
• By Mandy Jackson

News that US Food and Drug Administration Center for Biologics Evaluation and Research (CBER) director Peter Marks submitted his resignation, effective 5 April, late in the day on 28 March shook the b

Scrip

Beam Gets Important Proof Of Concept For AATD Therapy

 
• By Alaric DeArment

Beam Therapeutics sees BEAM-302 as having potential for eventual accelerated approval from the US Food and Drug Administration in alpha-1 antitrypsin deficiency (AATD) after announcing positive early

Scrip

Deal Watch: Amgen, CytomX Pull Back On Part Of T-Cell Engager Collaboration

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. CytomX, Amgen Decision Follows January